BioCentury | Feb 19, 2021
Product Development

Korea Spotlight: Eutilex readying first U.S. trial as cancer company aims for global stage

...Greater China, Korea and Taiwan.The Seoul-based company already has a deal in China for the antibody. Zhejiang Huahai Pharmaceutical Co. Ltd....
...in exchange for up to $35.5 million, including a $1 million upfront payment, plus royalties. Huahai...
...$32.3 million IPO on KOSDAQ in December 2018. The venture money included $30 million from Huahai...
BioCentury | Sep 26, 2019
Politics & Policy

MNCs gain ground in China’s centralized procurement

...which offered up to a 53% discount, while BMS shares its win for fosinopril with Zhejiang Huahai Pharmaceutical Co. Ltd....
...Three of the 25 drugs in the program are injectable. Hongjiang Li, Staff Writer AstraZeneca plc Bristol-Myers Squibb Co. Zhejiang Huahai Pharmaceutical Co. Ltd. Merck...
BioCentury | Sep 25, 2019
Politics & Policy

Additional price cuts in nationwide expansion of China’s centralized procurement

...bids for hypercholesterolemia and dyslipidemia drug rosuvastatin and hypertension and coronary artery disease drug amlodipine. Zhejiang Huahai Pharmaceutical Co. Ltd....
...Policy is Good News for Innovative Drug Developers” ). Hongjiang Li, Staff Writer Zhejiang Jingxin Pharmaceutical Co Ltd. Zhejiang Huahai Pharmaceutical Co. Ltd. China ...
BioCentury | Jun 19, 2019
Regulation

Why China’s 4 + 7 policy is good news for innovative drug developers

...time,” Hou said. For instance, last year FDA issued a recall and warning letter to Zhejiang Huahai Pharmaceutical Co. Ltd....
...importation of the API from Huahai due to impurities. In the first round procurement tender, Huahai...
...N.Y. Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland U.S. Food and Drug Administration (FDA), Silver Spring, Md. Zhejiang Huahai Pharmaceutical Co. Ltd....
BioCentury | Jan 18, 2019
Politics & Policy

Winners of China's centralized procurement to secure over 60% market share

...the tender for antiviral entecavir at a 90% price cut, gained HK$0.44 to HK$6.46; Zhejiang Huahai...
...Salubris Pharmaceuticals Co. Ltd. (SZSE:002294) added RMB0.45 to RMB21.20. Hongjiang Li Shenzhen Salubris Pharmaceuticals Co. Ltd. Sino Biopharmaceutical Ltd. Zhejiang Huahai Pharmaceutical Co. Ltd. Zhejiang...
BioCentury | Dec 7, 2018
Company News

Chinese biopharma stocks plummet after centralized tendering report

...Centralized Tendering Talks" ). Shanghai Securities News said other Chinese companies with successful bids include Zhejiang Huahai Pharmaceutical Co. Ltd....
...Group Ltd. (HKSE:1093) shares dropped HK$2.34 (14%) to HK$13.82. Jingxin gained RMB0.11 to RMB10, and Huahai...
...Pharmaceutical Group Co. Ltd. (Shanghai:600196; HKSE:2196), Shanghai, China Sino Biopharmaceutical Ltd. (HKSE:1177), Hong Kong, China Zhejiang Huahai Pharmaceutical Co. Ltd....
BioCentury | Dec 7, 2018
Company News

Chinese biopharma stocks plummet after centralized tendering report

...Centralized Tendering Talks" ). Shanghai Securities News said other Chinese companies with successful bids include Zhejiang Huahai Pharmaceutical Co. Ltd....
...Group Ltd. (HKSE:1093) shares dropped HK$2.34 (14%) to HK$13.82. Jingxin gained RMB0.11 to RMB10, and Huahai...
...contributed to this story. Sandi Wong Ascletis Pharmaceuticals Co. Ltd. Innovent Biologics Inc. Jiangsu Hengrui Medicine Co. Ltd. Sino Biopharmaceutical Ltd. Zhejiang Huahai Pharmaceutical Co. Ltd. Zhejiang...
BioCentury | Nov 10, 2017
Company News

Huahai gets license to Eutilex's EU-101

...Eutilex Co. Ltd. (Seoul, South Korea) granted Zhejiang Huahai Pharmaceutical Co. Ltd. (Shanghai:600521) exclusive rights to develop and commercialize preclinical...
...royalties if Eutilex commercializes EU-101 in markets other than those for which Huahai has rights. Huahai...
...Eutilex Co. Ltd., Seoul, South Korea Zhejiang Huahai Pharmaceutical Co. Ltd. (Shanghai:600521), Zhejiang, China Business: Cancer Elizabeth S. Eaton EU-101 Eutilex Co. Ltd. Zhejiang Huahai Pharmaceutical Co. Ltd. Tumor...
BioCentury | Nov 6, 2017
Company News

Huahai gets license to Eutilex's EU-101

...Eutilex Co. Ltd. (Seoul, South Korea) granted Zhejiang Huahai Pharmaceutical Co. Ltd. (Shanghai:600521) exclusive rights to develop and commercialize preclinical...
...million equity investment and is eligible for up to $35 million in milestones, plus royalties. Huahai...
...royalties if Eutilex commercializes EU-101 in markets other than those for which Huahai has rights. Huahai...
BioCentury | Jul 25, 2016
Strategy

Paving the way

...Ph III Pfizer Inc. (NYSE:PFE) Ph III Oncobiologics Inc. (NASDAQ:ONS) / Viropro Inc. (Pink:VPRO) / Zhejiang Huahai Pharmaceutical Co. Ltd....
Items per page:
1 - 10 of 14
BioCentury | Feb 19, 2021
Product Development

Korea Spotlight: Eutilex readying first U.S. trial as cancer company aims for global stage

...Greater China, Korea and Taiwan.The Seoul-based company already has a deal in China for the antibody. Zhejiang Huahai Pharmaceutical Co. Ltd....
...in exchange for up to $35.5 million, including a $1 million upfront payment, plus royalties. Huahai...
...$32.3 million IPO on KOSDAQ in December 2018. The venture money included $30 million from Huahai...
BioCentury | Sep 26, 2019
Politics & Policy

MNCs gain ground in China’s centralized procurement

...which offered up to a 53% discount, while BMS shares its win for fosinopril with Zhejiang Huahai Pharmaceutical Co. Ltd....
...Three of the 25 drugs in the program are injectable. Hongjiang Li, Staff Writer AstraZeneca plc Bristol-Myers Squibb Co. Zhejiang Huahai Pharmaceutical Co. Ltd. Merck...
BioCentury | Sep 25, 2019
Politics & Policy

Additional price cuts in nationwide expansion of China’s centralized procurement

...bids for hypercholesterolemia and dyslipidemia drug rosuvastatin and hypertension and coronary artery disease drug amlodipine. Zhejiang Huahai Pharmaceutical Co. Ltd....
...Policy is Good News for Innovative Drug Developers” ). Hongjiang Li, Staff Writer Zhejiang Jingxin Pharmaceutical Co Ltd. Zhejiang Huahai Pharmaceutical Co. Ltd. China ...
BioCentury | Jun 19, 2019
Regulation

Why China’s 4 + 7 policy is good news for innovative drug developers

...time,” Hou said. For instance, last year FDA issued a recall and warning letter to Zhejiang Huahai Pharmaceutical Co. Ltd....
...importation of the API from Huahai due to impurities. In the first round procurement tender, Huahai...
...N.Y. Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland U.S. Food and Drug Administration (FDA), Silver Spring, Md. Zhejiang Huahai Pharmaceutical Co. Ltd....
BioCentury | Jan 18, 2019
Politics & Policy

Winners of China's centralized procurement to secure over 60% market share

...the tender for antiviral entecavir at a 90% price cut, gained HK$0.44 to HK$6.46; Zhejiang Huahai...
...Salubris Pharmaceuticals Co. Ltd. (SZSE:002294) added RMB0.45 to RMB21.20. Hongjiang Li Shenzhen Salubris Pharmaceuticals Co. Ltd. Sino Biopharmaceutical Ltd. Zhejiang Huahai Pharmaceutical Co. Ltd. Zhejiang...
BioCentury | Dec 7, 2018
Company News

Chinese biopharma stocks plummet after centralized tendering report

...Centralized Tendering Talks" ). Shanghai Securities News said other Chinese companies with successful bids include Zhejiang Huahai Pharmaceutical Co. Ltd....
...Group Ltd. (HKSE:1093) shares dropped HK$2.34 (14%) to HK$13.82. Jingxin gained RMB0.11 to RMB10, and Huahai...
...Pharmaceutical Group Co. Ltd. (Shanghai:600196; HKSE:2196), Shanghai, China Sino Biopharmaceutical Ltd. (HKSE:1177), Hong Kong, China Zhejiang Huahai Pharmaceutical Co. Ltd....
BioCentury | Dec 7, 2018
Company News

Chinese biopharma stocks plummet after centralized tendering report

...Centralized Tendering Talks" ). Shanghai Securities News said other Chinese companies with successful bids include Zhejiang Huahai Pharmaceutical Co. Ltd....
...Group Ltd. (HKSE:1093) shares dropped HK$2.34 (14%) to HK$13.82. Jingxin gained RMB0.11 to RMB10, and Huahai...
...contributed to this story. Sandi Wong Ascletis Pharmaceuticals Co. Ltd. Innovent Biologics Inc. Jiangsu Hengrui Medicine Co. Ltd. Sino Biopharmaceutical Ltd. Zhejiang Huahai Pharmaceutical Co. Ltd. Zhejiang...
BioCentury | Nov 10, 2017
Company News

Huahai gets license to Eutilex's EU-101

...Eutilex Co. Ltd. (Seoul, South Korea) granted Zhejiang Huahai Pharmaceutical Co. Ltd. (Shanghai:600521) exclusive rights to develop and commercialize preclinical...
...royalties if Eutilex commercializes EU-101 in markets other than those for which Huahai has rights. Huahai...
...Eutilex Co. Ltd., Seoul, South Korea Zhejiang Huahai Pharmaceutical Co. Ltd. (Shanghai:600521), Zhejiang, China Business: Cancer Elizabeth S. Eaton EU-101 Eutilex Co. Ltd. Zhejiang Huahai Pharmaceutical Co. Ltd. Tumor...
BioCentury | Nov 6, 2017
Company News

Huahai gets license to Eutilex's EU-101

...Eutilex Co. Ltd. (Seoul, South Korea) granted Zhejiang Huahai Pharmaceutical Co. Ltd. (Shanghai:600521) exclusive rights to develop and commercialize preclinical...
...million equity investment and is eligible for up to $35 million in milestones, plus royalties. Huahai...
...royalties if Eutilex commercializes EU-101 in markets other than those for which Huahai has rights. Huahai...
BioCentury | Jul 25, 2016
Strategy

Paving the way

...Ph III Pfizer Inc. (NYSE:PFE) Ph III Oncobiologics Inc. (NASDAQ:ONS) / Viropro Inc. (Pink:VPRO) / Zhejiang Huahai Pharmaceutical Co. Ltd....
Items per page:
1 - 10 of 14